
Opinion|Videos|March 14, 2025
JAK V617F Monitoring and Risk Assessment Tools: Optimizing Treatment Decisions in MPN
Author(s)Daniel Landau, MD
An expert discusses how advances in JAK V617F monitoring have improved the assessment of disease status and guided treatment decisions and how risk assessment tools have transformed the ability to optimize treatment selection in patients with myeloproliferative neoplasms (MPNs).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please discuss how advances in JAK V617F monitoring have empowered you to better assess disease status and guide treatment decisions.
- Please share how risk assessment tools have transformed your ability to optimize treatment selection in patients with MPNs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
5


















